Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis CRoberta D’Ambrosio, S. Fagiuoli, Francesca Capelli et al.|Journal of Hepatology|2018Cited by 133
Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized studySilvia Fargion, Gemino Fiorelli, Anna Ludovica Fracanzani et al.|The American Journal of Gastroenterology|2002Cited by 80
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II studyRoberta D’Ambrosio, S. Fagiuoli, L. Pasulo et al.|Journal of Hepatology|2018Cited by 12
THU-131-Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: A real-life study from the NAVIGATORE Lombardia and Veneto NetworksElisabetta Degasperi, S. Fagiuoli, Angiola Spinetti et al.|Journal of Hepatology|2019Cited by 3
Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto NetworksElisabetta Degasperi, S. Fagiuoli, Angiola Spinetti et al.|Digestive and Liver Disease|2019Cited by 1